Extreme Athlete Anthony Anzell Doesn’t Let His Hereditary Hemmorhagic Telangiectasia Slow Him Down
Source: Pixabay

Extreme Athlete Anthony Anzell Doesn’t Let His Hereditary Hemmorhagic Telangiectasia Slow Him Down

Reported by Fox 2, Anthony Anzell doesn’t let his rare genetic disease hold him back. Anthony is an extreme athlete who just swam 19 miles, the entire length of Torch…

Continue Reading Extreme Athlete Anthony Anzell Doesn’t Let His Hereditary Hemmorhagic Telangiectasia Slow Him Down
PTC Therapeutics Continue To Fight For Duchenne Muscular Dystrophy Community
Source: Pixabay

PTC Therapeutics Continue To Fight For Duchenne Muscular Dystrophy Community

Even after the third denial from the U.S. FDA, Food and Drug Administration, PTC Therapeutics Incorporation will not stop fighting for the drug Translarna that they believe will help patients…

Continue Reading PTC Therapeutics Continue To Fight For Duchenne Muscular Dystrophy Community
ICYMI: FDA In Favor Of Luxturna, A Gene Therapy For Leber Congenital Amaurosis
Source: Pixabay

ICYMI: FDA In Favor Of Luxturna, A Gene Therapy For Leber Congenital Amaurosis

The FDA, US Food and Drug Administration, unanimously agreed upon the recommendation for a new gene therapy that treats a rare form of blindness, reported ScienceNordic. Spark Therapeutics, a biotech…

Continue Reading ICYMI: FDA In Favor Of Luxturna, A Gene Therapy For Leber Congenital Amaurosis
Ellie Simmonds, Paralympic Champion, Receives Honorary Degree From Swansea University
https://pixabay.com/en/gold-medal-winner-swimming-381749/

Ellie Simmonds, Paralympic Champion, Receives Honorary Degree From Swansea University

Ellie Simmonds is a dominate Paralympic swimmer having won five times in her 23-years and was honored locally for her success, reported Border Telegraph.  Just recently, she attended to a…

Continue Reading Ellie Simmonds, Paralympic Champion, Receives Honorary Degree From Swansea University
Midatech Pharma Gets Verbal Approval For MTD201 Continued Development
Source: Pixabay

Midatech Pharma Gets Verbal Approval For MTD201 Continued Development

Midatech Pharma just received verbal confirmation from Polish regulators to conduct the first European in-human study for a treatment that could potential aid those with carcinoid cancer and acromegaly, reported…

Continue Reading Midatech Pharma Gets Verbal Approval For MTD201 Continued Development
CureVac Partners with Arcturus Therapeutics to Target Ornithine Transcarbamylase Deficiency
Source: Pixabay

CureVac Partners with Arcturus Therapeutics to Target Ornithine Transcarbamylase Deficiency

Another successful partnership in the rare disease community has come to fruition, reports The Pharma Letter. Just this past week, CureVac and Arcturus Therapeutics will become a powerhouse together with…

Continue Reading CureVac Partners with Arcturus Therapeutics to Target Ornithine Transcarbamylase Deficiency